Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy

Daniel P. Judge, Stephen B. Heitner*, Rodney H. Falk, Mathew S. Maurer, Sanjiv J. Shah, Ronald M. Witteles, Martha Grogan, V. N. Selby, Daniel Jacoby, M. Hanna, Jose Nativi-Nicolau, Jignesh Patel, Satish Rao, Uma Sinha, Cameron W. Turtle, Jonathan C. Fox

*Corresponding author for this work

Research output: Contribution to journalArticle

31 Scopus citations

Abstract

Background: Transthyretin (TTR) amyloidosis is an underdiagnosed disease caused by destabilization of TTR due to pathogenic mutations or aging. Both pathogenic and protective mutations illuminate mechanisms of disease and potential interventions. AG10 is a selective, oral TTR stabilizer under development for transthyretin amyloidosis cardiomyopathy (ATTR-CM) that mimics a protective TTR mutation. Objectives: This randomized, double-blind, placebo-controlled study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of AG10 in ATTR-CM patients with symptomatic, chronic heart failure. Methods: ATTR-CM, New York Heart Association functional class II to III subjects (n = 49, mutant or wild-type) were randomized 1:1:1 to AG10 400 mg, AG10 800 mg, or placebo twice daily for 28 days. Safety and tolerability were assessed by clinical and laboratory criteria. AG10 plasma levels were measured. TTR stability was assessed by changes in serum TTR, and 2 established ex vivo assays (fluorescent probe exclusion and Western blot). Results: AG10 treatment was well-tolerated, achieved target plasma concentrations and demonstrated near-complete stabilization of TTR. TTR stabilization was more complete and less variable at the higher dose with stabilization by fluorescent probe exclusion of 92 ± 10% (mean ± SD) at trough and 96 ± 9% at peak (both p < 10−12 vs. placebo). Average serum TTR increased by 36 ± 21% and 51 ± 38% at 400 and 800 mg, respectively (both p < 0.0001 vs. placebo). Baseline serum TTR in treated subjects was below normal in 80% of mutant and 33% of wild-type subjects. AG10 treatment restored serum TTR to the normal range in all subjects. Conclusions: AG10 has the potential to be a safe and effective treatment for patients with ATTR-CM. A phase 3 trial is ongoing. (Study of AG10 in Amyloid Cardiomyopathy; NCT03458130)

Original languageEnglish (US)
Pages (from-to)285-295
Number of pages11
JournalJournal of the American College of Cardiology
Volume74
Issue number3
DOIs
StatePublished - Jul 23 2019

Keywords

  • AG10
  • ATTR-CM
  • amyloidosis
  • cardiomyopathy
  • heart failure
  • transthyretin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy'. Together they form a unique fingerprint.

  • Cite this

    Judge, D. P., Heitner, S. B., Falk, R. H., Maurer, M. S., Shah, S. J., Witteles, R. M., Grogan, M., Selby, V. N., Jacoby, D., Hanna, M., Nativi-Nicolau, J., Patel, J., Rao, S., Sinha, U., Turtle, C. W., & Fox, J. C. (2019). Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. Journal of the American College of Cardiology, 74(3), 285-295. https://doi.org/10.1016/j.jacc.2019.03.012